Expert Analysis on Recent Developments in DESTINY-Lung01 and DESTINY-Lung02 Trials

EP: 1.Beamion Lung 1: Zongertinib (BI 1810631) in Advanced HER2+ NSCLC

Now Viewing

EP: 2.Expert Analysis on Recent Developments in DESTINY-Lung01 and DESTINY-Lung02 Trials

EP: 3.Expert Perspectives on the Latest TROPION-Lung01 Data

EP: 4.EMPOWER-Lung3: Cemiplimab Plus Chemotherapy in Advanced NSCLC

EP: 5.EMPOWER-Lung1 and 3 Squamous Subgroup Analysis: Expert Insights

EP: 6.Future Perspectives on the Treatment of NSCLC

This is a video synopsis/ summary of an OncLive Insights® featuring Edgardo S. Santos, MD, FACP, FCCP.

Santos discussed updated findings of trastuzumab deruxtecan, an antibody-drug conjugate, for patients with non–small cell lung cancer (NSCLC) with HER2 mutations. Data from the DESTINY-Lung02 study compared the FDA-approved dose (5.4 mg/kg) with a higher 6.4-mg/kg dose. Both had high response rates, but more intestinal toxicity occurred with the 5.4-mg/kg dose. An ongoing first-line phase 3 trial, DESTINY-Lung04, is now testing trastuzumab deruxtecan versus platinum chemotherapy plus immunotherapy.

Additionally, a pooled analysis from DESTINY-Lung01 and DESTINY-Lung02 focused on patients with brain metastases. The key finding was that systemic response rates to trastuzumab deruxtecan were similar between those with vs those without brain metastases. As expected, survival outcomes remained inferior for patients with baseline brain metastases. However, intracranial response rates were observed with both doses of trastuzumab deruxtecan, slightly higher for the 6.4-mg/kg dose, including some complete responses. In summary, extracranial efficacy of trastuzumab deruxtecan appears consistent among patients with NSCLC regardless of brain metastasis status.

Video synopsis is AI-generated and reviewed by OncLive® editorial staff.